Ravi Savarirayan
Comment: Unreferenced, only cites works (co-)authored by this person - where does the other information come from? DoubleGrazing (talk) 06:23, 15 October 2026 (UTC)
- Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. Skeldysp (talk) 00:26, 15 October 2026 (UTC)
Ravi Savarirayan
Professor Ravi Savarirayan is an Australian interventional clinical geneticist and Professor of Human (Clinical) Genetics at the Murdoch Children's Research Institute (MCRI) in Melbourne, Victoria, Australia. He is a leading figure in interventional genetics for skeletal dysplasia, serving as the global lead investigator on the clinical trial programs that are investigating precision therapies for achondroplasia, including vosoritide, navepegritide, infigratinib, and dabogratinib.
Education and Career
Savarirayan received his MBBS from the University of Adelaide in 1990, became a fellow of the Royal Australasian College of Physicians in 1997, and received an MD from the University of Melbourne in 2004. He subsequently joined the Murdoch Children's Research Institute, where he is now Professor of Human (Clinical) Genetics and Group Leader of the Molecular Therapies research group within MCRI's Genomic Medicine research area. Alongside this, he holds a Professorial Fellowship at the University of Melbourne, works as a consultant clinical geneticist at Victorian Clinical Genetics Services (VCGS), and is a pediatrician at The Royal Children's Hospital, Melbourne.
Savarirayan has held leadership roles in organizations concerned with skeletal dysplasia. He served as president of the International Skeletal Dysplasia Society, was a founding member of the Skeletal Dysplasia Management Consortium, and founded the Society for Interventional Genetics, an organization established to support precision-medicine approaches for rare genetic conditions and training in interventional genetics.
Research
Savarirayan's research centers on inherited disorders of the skeleton, particularly skeletal dysplasia conditions that cause disproportionate short stature, joint disease, and osteoporosis. His group's work spans basic and translational research into the genetic and molecular basis of these conditions through to their clinical management and the design and conduct of international clinical trials examining both growth outcomes and the longer-term health outcomes and complications associated with mechanism-based treatments for achondroplasia.
Much of his research has focused on achondroplasia and related FGFR3-associated skeletal dysplasia. He led international consensus efforts to standardize diagnosis, care, and treatment of skeletal dysplasia conditions, including first authorship of an international consensus statement on the diagnosis, multidisciplinary management, and lifelong care of people with achondroplasia[1], developed with the participation of 55 international experts and patient representatives. One of his most prominent research contributions has been leading the clinical trial programs for four precision therapies for achondroplasia: vosoritide[2][3][4][5], navepegritide[6][7], infigratinib[8][9], and dabogratinib. As of 2026, he has authored or co-authored more than 250 peer-reviewed publications and collaborated with researchers across roughly 44 countries[10][11][12].
Service and Health Equity Work
Outside his academic work, Savarirayan is a co-founder of Yatra Foundation Australia, which supports education and community-welfare initiatives for disadvantaged children in rural and remote areas of India. His health-services research has also examined disparities in access to culturally safe clinical-genetics services for Aboriginal and Torres Strait Islander peoples. He has publicly advocated broader access to treatments for skeletal dysplasia, including through publicly funded health systems, and has led international guidance intended to support consistent implementation of care across different countries.
Awards
· Australian Fulbright Professional Scholarship (1998)
· MCRI Research Excellence Award (2020)
· Named one of MCRI's 30 “Brilliant Minds,” marking the institute's 30th anniversary
· NHMRC Leadership Fellowship
References
- ↑ Savarirayan, Ravi; Ireland, Penny; Irving, Melita; Thompson, Dominic; Alves, Inês; Baratela, Wagner A. R.; Betts, James; Bober, Michael B.; Boero, Silvio; Briddell, Jenna; Campbell, Jeffrey; Campeau, Philippe M.; Carl-Innig, Patricia; Cheung, Moira S.; Cobourne, Martyn (2022-03). "International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia". Nature Reviews Endocrinology. 18 (3): 173–189. doi:10.1038/s41574-021-00595-x. ISSN 1759-5029. Check date values in:
|date=(help) - ↑ Savarirayan, Ravi; Wilcox, William R; Harmatz, Paul; Phillips, John; Polgreen, Lynda E; Tofts, Louise; Ozono, Keiichi; Arundel, Paul; Irving, Melita; Bacino, Carlos A; Basel, Donald; Bober, Michael B; Charrow, Joel; Mochizuki, Hiroshi; Kotani, Yumiko (2024-01). "Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial". The Lancet Child & Adolescent Health. 8 (1): 40–50. doi:10.1016/S2352-4642(23)00265-1. Check date values in:
|date=(help) - ↑ Savarirayan, Ravi; Tofts, Louise; Irving, Melita; Wilcox, William; Bacino, Carlos A; Hoover-Fong, Julie; Ullot Font, Rosendo; Harmatz, Paul; Rutsch, Frank; Bober, Michael B; Polgreen, Lynda E; Ginebreda, Ignacio; Mohnike, Klaus; Charrow, Joel; Hoernschemeyer, Daniel (2020-09). "Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial". The Lancet. 396 (10252): 684–692. doi:10.1016/S0140-6736(20)31541-5. Check date values in:
|date=(help) - ↑ Savarirayan, Ravi; Irving, Melita; Bacino, Carlos A.; Bostwick, Bret; Charrow, Joel; Cormier-Daire, Valerie; Le Quan Sang, Kim-Hanh; Dickson, Patricia; Harmatz, Paul; Phillips, John; Owen, Natalie; Cherukuri, Anu; Jayaram, Kala; Jeha, George S.; Larimore, Kevin (2019-07-04). "C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia". New England Journal of Medicine. 381 (1): 25–35. doi:10.1056/NEJMoa1813446. ISSN 0028-4793.
- ↑ Savarirayan, Ravi; Hoover-Fong, Julie; Ozono, Keiichi; Backeljauw, Philippe; Cormier-Daire, Valérie; DeAndrade, Kristen; Ireland, Penny; Irving, Melita; Llerena Junior, Juan; Maghnie, Mohamad; Menzel, Margaret; Merchant, Nadia; Mohnike, Klaus; Iruretagoyena, Susana Noval; Okada, Keita (2025-05). "International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia". Nature Reviews Endocrinology. 21 (5): 314–324. doi:10.1038/s41574-024-01074-9. ISSN 1759-5029. Check date values in:
|date=(help) - ↑ Savarirayan, Ravi; Hoernschemeyer, Daniel G.; Ljungberg, Merete; Zarate, Yuri A.; Bacino, Carlos A.; Bober, Michael B.; Legare, Janet M.; Högler, Wolfgang; Quattrin, Teresa; Abuzzahab, M. Jennifer; Hofman, Paul L.; White, Klane K.; Ma, Nina S.; Schnabel, Dirk; Sousa, Sérgio B. (2023-11). "Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial". eClinicalMedicine. 65: 102258. doi:10.1016/j.eclinm.2023.102258. PMC 10562841 Check
|pmc=value (help). PMID 37823031 Check|pmid=value (help). Check date values in:|date=(help) - ↑ Savarirayan, Ravi; McDonnell, Ciara; Bacino, Carlos A.; Hoernschemeyer, Daniel G.; Legare, Janet M.; Abuzzahab, M. Jennifer; Hofman, Paul L.; Campeau, Philippe M.; de Bergua Domingo, Josep Maria; Ward, Leanne M.; Smit, Kevin; Smith, Alden; Mao, Meng; Ominsky, Michael S.; Freiberg, Lærke C. (2026-01-01). "Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial". JAMA Pediatrics. 180 (1): 18. doi:10.1001/jamapediatrics.2025.4771. ISSN 2168-6203. PMC 12624480 Check
|pmc=value (help). PMID 41247754 Check|pmid=value (help). - ↑ Savarirayan, Ravi; De Bergua, Josep Maria; Arundel, Paul; Salles, Jean Pierre; Saraff, Vrinda; Delgado, Borja; Leiva-Gea, Antonio; McDevitt, Helen; Nicolino, Marc; Rossi, Massimiliano; Salcedo, Maria; Cormier-Daire, Valerie; Skae, Mars; Kannu, Peter; Phillips, John (2025-02-27). "Oral Infigratinib Therapy in Children with Achondroplasia". New England Journal of Medicine. 392 (9): 865–874. doi:10.1056/NEJMoa2411790. ISSN 0028-4793.
- ↑ Savarirayan, Ravi; Hoover-Fong, Julie; Irving, Melita; Arundel, Paul; de Bergua, Josep Maria; Campeau, Philippe M.; Candler, Toby; Cocanougher, Benjamin T.; Cormier-Daire, Valerie; Edouard, Thomas; Fredwall, Svein O.; Harmatz, Paul; Hoernschemeyer, Daniel; Irgens, Henrik U.; Jamuar, Saumya (2026-09-03). "Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia". New England Journal of Medicine. 395 (9): 859–869. doi:10.1056/NEJMoa2604565. ISSN 0028-4793.
- ↑ Savarirayan, Ravi (2024-08). "Advances in the management of achondroplasia". Nature Reviews Endocrinology. 20 (8): 443–444. doi:10.1038/s41574-024-00994-w. ISSN 1759-5029. Check date values in:
|date=(help) - ↑ Dauber, Andrew; Cheung, Moira S.; Hoover-Fong, Julie; Fredwall, Svein Otto; AlSayed, Moeenaldeen; Boero, Silvio; Calder, Alistair D.; Cormier-Daire, Valérie; Fano, Virginia; Kubota, Takuo; Kunkel, Philip; Llerena Junior, Juan; Maghnie, Mohamad; Mortier, Geert; Namba, Noriyuki (2026-08-20). "Diagnosis of hypochondroplasia: international Delphi consensus recommendations". Nature Reviews Endocrinology. doi:10.1038/s41574-026-01296-z. ISSN 1759-5029.
- ↑ Savarirayan, Ravi; Hoover-Fong, Julie; Yap, Patrick; Fredwall, Svein O (2024-04). "New treatments for children with achondroplasia". The Lancet Child & Adolescent Health. 8 (4): 301–310. doi:10.1016/S2352-4642(23)00310-3. Check date values in:
|date=(help)
This article "Ravi Savarirayan" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Ravi Savarirayan. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
